Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

cbdMD, Inc.

YCBDAMEX
Healthcare
Drug Manufacturers - Specialty & Generic
$0.92
$0.009(0.95%)
U.S. Market is Open • 14:27

cbdMD, Inc. Fundamental Analysis

cbdMD, Inc. (YCBD) shows weak financial fundamentals with a PE ratio of -0.02, profit margin of -6.51%, and ROE of -14.53%. The company generates $5.9B in annual revenue with weak year-over-year growth of -1.50%.

Key Strengths

Cash Position40.03%
PEG Ratio-0.02

Areas of Concern

ROE-14.53%
Operating Margin-5.73%
Current Ratio0.00
We analyze YCBD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -143.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-143.6/100

We analyze YCBD's fundamental strength across five key dimensions:

Efficiency Score

Weak

YCBD struggles to generate sufficient returns from assets.

ROA > 10%
-27.81%

Valuation Score

Excellent

YCBD trades at attractive valuation levels.

PE < 25
-0.02
PEG Ratio < 2
-0.02

Growth Score

Moderate

YCBD shows steady but slowing expansion.

Revenue Growth > 5%
-1.50%
EPS Growth > 10%
39.11%

Financial Health Score

Moderate

YCBD shows balanced financial health with some risks.

Debt/Equity < 1
0.07
Current Ratio > 1
0.00

Profitability Score

Weak

YCBD struggles to sustain strong margins.

ROE > 15%
-1452.71%
Net Margin ≥ 15%
-6.51%
Positive Free Cash Flow
No

Key Financial Metrics

Is YCBD Expensive or Cheap?

P/E Ratio

YCBD trades at -0.02 times earnings. This suggests potential undervaluation.

-0.02

PEG Ratio

When adjusting for growth, YCBD's PEG of -0.02 indicates potential undervaluation.

-0.02

Price to Book

The market values cbdMD, Inc. at 0.00 times its book value. This may indicate undervaluation.

0.00

EV/EBITDA

Enterprise value stands at 2.02 times EBITDA. This is generally considered low.

2.02

How Well Does YCBD Make Money?

Net Profit Margin

For every $100 in sales, cbdMD, Inc. keeps $-6.51 as profit after all expenses.

-6.51%

Operating Margin

Core operations generate -5.73 in profit for every $100 in revenue, before interest and taxes.

-5.73%

ROE

Management delivers $-14.53 in profit for every $100 of shareholder equity.

-14.53%

ROA

cbdMD, Inc. generates $-27.81 in profit for every $100 in assets, demonstrating efficient asset deployment.

-27.81%

Following the Money - Real Cash Generation

Operating Cash Flow

cbdMD, Inc. generates limited operating cash flow of $-593.16M, signaling weaker underlying cash strength.

$-593.16M

Free Cash Flow

cbdMD, Inc. generates weak or negative free cash flow of $-993.83M, restricting financial flexibility.

$-993.83M

FCF Per Share

Each share generates $-94.69 in free cash annually.

$-94.69

FCF Yield

YCBD converts -88.72% of its market value into free cash.

-88.72%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.02

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.001

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.002

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.07

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.003

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.15

vs 25 benchmark

ROA

Return on assets percentage

-27.81

vs 25 benchmark

ROCE

Return on capital employed

0.10

vs 25 benchmark

How YCBD Stacks Against Its Sector Peers

MetricYCBD ValueSector AveragePerformance
P/E Ratio-0.0229.43 Better (Cheaper)
ROE-14.53%800.00% Weak
Net Margin-6.51%-20145.00% (disorted) Weak
Debt/Equity0.070.30 Strong (Low Leverage)
Current Ratio0.004.64 Weak Liquidity
ROA-2780.98%-17936.00% (disorted) Weak

YCBD outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews cbdMD, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-88.83%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-103.95%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

96.68%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ